N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]octadecanamide | 67964-87-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]octadecanamide
• CAS: 67964-87-8
• 化学式: C₂₈H₄₆N₂O₂
• 分子量: 442.7
• InChiKey: FKWHKBXVLNKTGT-UHFFFAOYSA-N

物化性质

• 沸点：
  652.4±45.0 °C(Predicted)
• 密度：
  1.014±0.06 g/cm3(Predicted)
• 溶解度：
  乙醇中≤2.5mg/ml；DMSO中≤20mg/ml；二甲基甲酰胺中≤20mg/ml

计算性质

• 辛醇/水分配系数(LogP)：
  8.9
• 重原子数：
  32
• 可旋转键数：
  19
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  65.1
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  stearoyl-CoA(4-) 、 5-hydroxytryptamine 生成 coenzyme A 、 氢(+1)阳离子 、 N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]octadecanamide
  参考文献：
  名称：

  Identification of an arylalkylamineN-acyltransferase fromDrosophila melanogasterthat catalyzes the formation of long-chainN-acylserotonins

  摘要：

  Arylalkylamine N‐acyltransferase‐like 2 2 (AANATL2) from Drosophila melanogaster was expressed and shown to catalyze the formation of long‐chain N‐acylserotonins and N‐acydopamines. Subsequent identification of endogenous amounts of N‐acylserotonins and colocalization of these fatty acid amides and AANATL2 transcripts gives supporting evidence that AANATL2 has a role in the biosynthetic formation of these important cell signalling lipids.

  DOI：

  10.1016/j.febslet.2013.12.027

文献信息

• Compounds, Compositions and Methods for Making the Same
  申请人：Vafai Scott

  公开号：US20090264496A1

  公开（公告）日：2009-10-22

  The present invention provides compounds and/or compositions that modulate PP2A methylation and/or activity and methods for preparing the same, which are useful for modulating the demethylation of PP2A, modulating the methylation of PP2A and/or modulating the activity of PP2A.

  本发明提供了能够调节PP2A甲基化和/或活性的化合物和/或组合物，以及制备这些化合物和/或组合物的方法。这些化合物和/或组合物可用于调节PP2A的去甲基化、甲基化和/或活性。
• Tryptamide compositions and methods of use
  申请人：Signum Biosciences, Inc.

  公开号：US10314817B2

  公开（公告）日：2019-06-11

  EHT extract including a mixture of late eluting tryptamides and early eluting tryptamides in a weight ratio of at least about 7:1 late eluting tryptamides:early eluting tryptamides, wherein the EHT extract includes at least 30% eicosanoyl-5-hydroxytryptamide, based on the total weight of the tryptamides in the EHT extract.

  EHT提取物，包括晚洗脱胰酰胺和早洗脱胰酰胺的混合物，晚洗脱胰酰胺与早洗脱胰酰胺的重量比至少约为7:1，其中EHT提取物包括至少30%的二十烷酰-5-羟基色酰胺（基于EHT提取物中胰酰胺的总重量）。
• Compounds, compositions and methods for making the same
  申请人：Signum Biosciences, Inc.

  公开号：US10583119B2

  公开（公告）日：2020-03-10

  The present invention provides compounds and/or compositions that modulate PP2A methylation and/or activity and methods for preparing the same, which are useful for modulating the demethylation of PP2A, modulating the methylation of PP2A and/or modulating the activity of PP2A.

  本发明提供了调节 PP2A 甲基化和/或活性的化合物和/或组合物以及制备方法，这些化合物和/或组合物可用于调节 PP2A 的去甲基化、调节 PP2A 的甲基化和/或调节 PP2A 的活性。
• TRYPTAMIDE COMPOSITIONS AND METHODS OF USE
  申请人：Signum Biosciences, Inc.

  公开号：EP3207029B1

  公开（公告）日：2021-08-04
• COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME
  申请人：Signum Biosciences, Inc.

  公开号：US20170266161A1

  公开（公告）日：2017-09-21

  The present invention provides compounds and/or compositions that modulate PP2A methylation and/or activity and methods for preparing the same, which are useful for modulating the demethylation of PP2A, modulating the methylation of PP2A and/or modulating the activity of PP2A.